NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
PET Response Adapted Design Comparing ABVD +/- ISRT with A2VD +/- ISRT in Patients with Stage IA/IIA Hodgkin Lymphoma (RADAR)
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
A Biomarker Sub-study of the CCTG ME.13 Duration of Anti PD-1 Therapy in Metastatic Melanoma STOP-GAP Trial
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MYELOMATCH) for the NCI myeloMATCH clinical trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
Clinical trials are an important option to consider for anyone being treated for cancer. Here is a listing of recent CCTG trials that are open to patient enrollment.
For trials by disease location:
The purpose of this study is to find out if the combination of a new drug and a commonly used drug is better than the commonly used drug alone at preventing this type of breast cancer from returning.
The purpose of this study is to compare the usual treatment of breast radiation and hormonal drugs after lumpectomy to using hormonal drugs alone for 50 to 70 year old people with low risk breast cancer. The removal of breast radiation from the usual treatment may have no effect on whether your cancer returns, and it could also reduce side effects.
The purpose of this study is to find out if a new drug helps prevent your inflammatory breast cancer from returning when given with radiotherapy.
The purpose of this study is to determine which approach, less frequent or more frequent monitoring, will lead to better outcomes for patients with pancreatic cysts.
Currently, the effectiveness of any pancreatic cyst monitoring strategy is unknown. Patients and physicians are eager to learn which strategy is better for this very common condition.
The purpose of this study is to find out what effects adding a new drug to the standard treatment has on you and your gastroesophageal cancer compared to the standard treatment given alone.
The purpose of this study is to test if we can determine what kind of chemotherapy to offer patients based on whether or not circulating tumour DNA (ctDNA) is found in a blood test taken after surgery for colon cancer.
Using ctDNA testing to determine what kind of chemotherapy to use is a new approach. This approach seems promising, but it is not clear if it can offer better results than standard treatment.
The purpose of this study is to compare a retreatment with Peptide Receptor Radionuclide Therapy (PRRT) to the standard treatment for your neuroendocrine cancer.
The drug being studied is a new type of drug approved for the treatment of neuroendocrine tumours (NETs). The new drug has been shown to shrink tumours in many people and seems promising, but it is not clear if receiving this drug again can offer better results than standard treatment.
The purpose of this study is to compare the effects on you and your prostate cancer of getting a higher dose of radiation therapy given over a shorter period of time compared to the current way radiation therapy is used to treat prostate cancer.
The purpose of this study is to see if adding a new drug to other drugs which are commonly used to treat metastatic urothelial cancer is better than the commonly used drugs alone.
The purpose of this study is to identify people who may not require treatment after surgery or may require less treatment after surgery because their cancer is at such a low risk of coming back based on the specific tumour features found by the laboratory testing and the extent of tumour spread. Receiving no treatment or less treatment can result in no or fewer side effects (fatigue, hair loss, bowel and bladder irritation).
The purpose of this study is to compare the effects on you and your endometrial cancer of a new drug in combination with radiation therapy compared to the current standard treatment of radiation therapy alone.
The purpose of this study is to compare the effects on you and your oropharyngeal cancer of radiotherapy to your neck guided by lymph node mapping (lymphatic mapping) using a special X-ray called Single Photon Emission Computed Tomography (SPECT-CT) compared to the current standard treatment where radiotherapy is given to both sides of the neck.
One of the treatments for multiple myeloma is with three medicines, all continued indefinitely until they stop working, or side effects happen. Two are tablets, and the third is an injection. In this study, we are testing if the injection can be stopped after around 18 months of treatment with no change to how your multiple myeloma is being controlled.
The purpose of this study is to compare the usual treatment for your Hodgkin lymphoma, which is a standard combination of four drugs, versus the standard combination with one drug of the combination replaced with a new drug that we hope will be more effective and cause you fewer side effects.
The purpose of this trial is to find out if people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) will live longer and have a better quality of life if they start treatment earlier. Some people do not have major symptoms when they are diagnosed with CLL or SLL. Treatment is often started when they show symptoms such as fever, anemia, or night sweats. Studies have shown that early treatment using older chemotherapy drugs doesn’t improve outcomes compared to later treatment.
The purpose of this study is to compare the use of magnetic resonance imaging (MRI) surveillance combined with prophylactic cranial irradiation (PCI) to MRI surveillance alone in treating your lung cancer that can sometimes spread to the brain.
MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain.
The purpose of this study is to compare the effects on you and your mucosal melanoma of a new drug with the usual treatment compared to a placebo with the usual treatment.
The purpose of this study is to compare the effects of receiving chemotherapy before surgery on you and your sarcoma compared to surgery alone.
The purpose of this study is to test if a mindfulness program (Mindfulness Based Cancer Survivorship (MBCS) Journey) delivered through a mobile smartphone application (Am Mindfulness) can reduce ongoing psychosocial symptoms such as stress, anxiety, depression, fatigue, and fear of cancer recurrence or progression that are often experienced by survivors.